The Hong Kong Polytechnic University (PolyU) has announced a formal collaboration with Shanghai ChemPartner Co., Ltd. to jointly develop next-generation cancer immunotherapy agents. This partnership combines expertise from both academia and industry, with the long-term goal of benefiting cancer patients. PolyU's novel targets will be further developed into antibody-based, personalized cancer treatments. The collaboration leverages the university's strengths in basic science research and the industry's commercialization expertise, creating a synergistic relationship. The partnership aims to bridge the gap from foundational research to therapeutic drug development, thereby accelerating the innovation and commercialization of groundbreaking cancer treatments. This synergy not only fosters the exchange of knowledge and resources but also paves the way for significant advancements in oncology.
The signing of Memorandum of Understanding (MOU) was held on 9 August 2024 to establish the partnership. The MOU was signed by Prof. Larry Ming Cheung CHOW, Head of the Department of Applied Biology and Chemical Technology at PolyU, and Mr. Shixin FAN, Board Director of Shanghai ChemPartner Co. Ltd.
Prof. Larry Ming Cheung Chow expressed his excitement about the collaboration, stating, "This partnership exemplifies the need for academia and industry to work closely together to achieve success. To create a win-win situation, we will focus on the early discovery phase of markers, while ChemPartner will work on the later stages of antibody development."
Mr. William Woo, Chairman and CEO of ChemPartner, emphasized the significance of this collaboration, saying, "Our cooperation with the Hong Kong Polytechnic University is a major event for ChemPartner. We hope that through this partnership, we can promote exchanges and collaboration between the two sides in the field of medical technology, share resources, complement each other's strengths, and jointly make greater contributions to human health."
理大與睿智醫藥合作開發新一代癌症免疫療法
香港理工大學 (理大) 宣佈與上海睿智醫藥有限公司(睿智醫藥)正式建立合作關係，共同開發新一代癌症免疫療法藥物。此次合作將結合學術界和醫藥業界的專業知識，以造福癌症患者為長期目標。理大發現的新靶點將得到進一步開發成基於抗體的個性化癌症治療藥物。大學基礎科學研究能力與業界商業化專業知識的結合是完美的合作方式。雙方合作將充分利用各自的優勢資源，從基礎研究到治療性藥物開發，實現無縫過渡，加速創新癌症治療方法的研發和市場推廣。這不僅促進了知識和資源的共用，還為癌症治療的創新和突破創造了有利條件。
雙方於2024年8月9日簽署合作諒解備忘錄，建立合作關係。備忘錄由理大應用生物和化學科技學系系主任周銘祥教授和上海睿智醫藥有限公司董事樊世新先生代表簽署。
周銘祥教授表示："理大與睿智醫藥的合作是一個非常激動人心的時刻。這次合作體現了學術界和業界需要更緊密地合作才能取得成功。為了實現雙贏，我們將專注於標記物的早期發現階段，而睿智醫藥將致力於抗體開發的後期階段。"
睿智醫藥董事長兼首席執行官胡瑞連先生表示："與香港理工大學的合作是睿智醫藥發展史上的一件大事，我們期待通過這次合作，能夠促進雙方在醫藥科技領域的交流與合作，實現資源分享，優勢互補，共同為人類的健康事業做出更大的貢獻。"
 |
PolyU and ChemPartner signed a MOU on 9 August 2024 to establish a formal collaboration. The MOU was signed by Prof. Larry Ming Cheung Chow (3rd from right) and Mr. Shixin Fan, Board Director of ChemPartner (3rd from left). Other guests joining the ceremony included Mr. William Woo, Chairman and CEO of ChemPartner (2nd from left), Mr. Yinqun Zha, CFO of ChemPartner (1st from left), Prof. Yanxiang Zhao, Associate Head and Professor of Department of Applied Biology and Chemical Technology at PolyU (2nd from right) and Prof. Thomas Leung, Professor at Department of Applied Biology and Chemical Technology at PolyU (1st from right). 理大與睿智醫藥於2024年8月9日簽署合作諒解備忘錄，由理大應用生物和化學科技學系系主任周銘祥教授（右三）和上海睿智醫藥有限公司董事樊世新先生（左三）代表簽署。其他出席嘉賓包括睿智醫藥董事長兼首席執行官胡瑞連先生、睿智醫藥首席財務官查胤群先生、理大應用生物和化學科技學系副系主任趙燕湘教授及理大應用生物及化學科技學系梁潤松教授。 |
The Hong Kong Polytechnic University (PolyU)
PolyU is committed to the development of biopharmaceuticals in Hong Kong. It has developed the first undergraduate degree in biotechnology (Bachelor of Science (Honours) in Applied Biology with Biotechnology) and the first Master degree in Biopharmaceutical Development and Commercialization in Hong Kong. The State Key Laboratory of Chemical Biology and Drug Discovery and other life sciences departments in PolyU have worked on the development of various anticancer drug and clinical devices.
For more information, please visit: www.polyu.edu.hk
香港理工大學（理大）
理大致力發展香港生物製藥。 它在香港開設了第一個生物技術本科學位（應用生物兼生物科技(榮譽)理學士學位）和生物醫藥研發及產業化理學碩士。 理大化學生物學與藥物發現國家重點實驗室及其他生命科學部門致力於多種抗癌藥物和臨床設備的開發。
